Recent Finacing
Recent Raise
Quell Therapeutics develops engineered Treg cell therapies and a modular platform—Phenotype‑Lock, CAR tissue‑targeting modules—for autologous/allogeneic CAR‑Treg products, advancing QEL‑001 for liver transplant and autoimmune/neuroinflammatory programs.
